Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

In the ELM-2 study (NCT03888105) of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) ( = 141), odronextamab 160 mg weekly (after step-up dosing) significantly improved Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Subscale (LymS, least squares mean [95% confidence interval], 3.02 [1.76, 4.

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

With up to 10 years of follow-up, we report results from the final analysis of RESONATE-2 (NCT01722487/NCT01724346), a phase 3 study of first-line ibrutinib versus chlorambucil for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients aged ≥65 years with previously untreated CLL/SLL without del(17p) were randomly assigned to receive either single-agent ibrutinib (420 mg/day; n = 136) or chlorambucil (0.5-0.

A rare case of Rosai-Dorfman disease mimicking a malignant lymphoproliferative process and IgG4-related disease.

Rosai-Dorfman disease (RDD), or sinus histiocytosis with massive lymphadenopathy, is a rare histiocytic disorder that often mimics malignancies and immune-mediated conditions such as IgG4-related disease (IgG4-RD). We report a 73-year-old male with a 2-year history of systemic symptoms, including fever, significant weight loss, and generalised lymphadenopathy, accompanied by strikingly elevated IgG4 levels. Advanced imaging revealed metabolically active lesions in lymph nodes, paranasal sinuses, and bones, complicating the differential diagnosis and raising concerns for malignancy or IgG4-RD.

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ Mutation: SEQUOIA Arm D Results.

Purpose: Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or mutation (mut) comprised a small percentage of study populations or were excluded entirely. The purpose of the SEQUOIA Arm D cohort was to evaluate the combination of zanubrutinib + venetoclax in treatment-naïve (TN) patients with CLL/small lymphocytic lymphoma (SLL), in a large population of patients with -aberrant disease.

Patients And Methods: Arm D is a nonrandomized cohort of patients aged 65 years and older (or 18-64 years with comorbidities).

Venetoclax used alone, or in combination with cladribine, changes the expression of apoptosis-regulating genes in chronic lymphocytic leukemia cells in vitro.

Background: Venetoclax (VEN) and cladribine (2-CdA) are active agents in the treatment of chronic lymphocytic leukemia (CLL), although their precise pro-apoptotic mechanisms in CLL cells remain unclear. However, in vitro studies suggest that these drugs may alter the expression of several proteins involved in apoptosis.

Objectives: The aim of the study was to evaluate the effect of VEN and 2-CdA, used individually and in combination, on the expression of apoptosis-related genes in CLL cells in vitro.

A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type.

Primary cutaneous diffuse large B cell lymphoma, leg type (PCDLBCL-LT) is an aggressive B cell extranodal variant of lymphoma present in the skin, typically without evidence of extra cutaneous spread at the time of diagnosis. PCDLBCL-LT accounts for 20% of all primary cutaneous B cell lymphomas (CBCL) and 5% of all primary cutaneous lymphomas (PCL). It is more common in the elderly (median age 75 years).

Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Introduction: Accelerated chronic lymphocytic leukemia (A-CLL) is a rare histological variant of CLL, which is associated with an aggressive clinical presentation and worse prognosis. The aim was to study the characteristics and treatment outcomes of A-CLL patients.

Material And Methods: The retrospective analysis included 106 A-CLL patients treated in Poland between 2013 and 2023.

Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?

Introduction: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. Although treatment has shifted from immunochemotherapy to novel targeted drugs over the last 10 years, novel therapies remain under investigation, particularly in relapsed and refractory patients.

Areas Covered: This review describes the use of approved targeted drugs and novel therapies in treatment-naïve and relapsed or refractory CLL.

Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice.

In the recent 2024 ESMO guidelines, the combination of venetoclax and ibrutinib was listed as one of the first-line treatment options for CLL patients. These drugs were first-in-class medicines that revolutionized CLL management, extending patients' overall survival even in cases refractory to immunochemotherapy. However, since the approval of both compounds, more and more Bruton Tyrosine Kinase inhibitors (BTKis) and B-cell lymphoma 2 inhibitors (BCL2is) have been discovered.

Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.

The most common form of Richter transformation, observed in 90-95% of patients, is the transformation of chronic lymphocytic leukemia (CLL) into diffuse large B-cell lymphoma (DLBCL). CLL has also been found to transform into Hodgkin lymphoma, prolymphocytic leukemia, and, in extremely rare cases, into other hematological malignancies, including Burkitt lymphoma (BL). This manuscript discusses a case of CLL transforming into BL and reviews a rare collection of cases of Burkitt lymphoma or Burkitt-like lymphoma associated with CLL,B-cell prolymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma and splenic marginal zone lymphoma.

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.

Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab (BR). We report the final analyses of MURANO (median follow-up, 7 years). Patients were randomized to VenR (venetoclax 400 mg daily for 2 years plus monthly rituximab for 6 months; n = 194) or BR (6 months; n = 195).

Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what's best for patient quality of life?

Introduction: In recent years, chronic lymphocytic leukemia (CLL) treatment has changed dramatically. Chemoimmunotherapy with fludarabine/cladribine, cyclophosphamide, and rituximab have been almost completely replaced by targeted therapies with small molecules, such as Bruton's tyrosine kinase inhibitors or B-cell lymphoma 2 (BCL-2) antagonists. However, few studies have assessed the impact of novel therapies on patient quality of life (QoL).

Atypical Hairy Cell Leukemia-The Current Status and Future Directions.

Hairy cell leukemia (HCL) is a rare, chronic lymphoid leukemia characterized by circulating lymphocytes with pale, hair-like cytoplasmic projections, pancytopenia, marked monocytopenia, and splenomegaly. Classic HCL displays distinct morphological, immunophenotypical, and genetic features. Classic HCL cells exhibit central nuclei, abundant cytoplasm with hair-like projections, and expression of CD20, CD22, CD11c, CD103, CD25, CD123, TBX21, annexin A1 (ANXA1), FMC7, CD200, and weak cyclin D1 (CCND1).

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.

JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.

The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review.

Introduction: Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adult patients. The landscape of CLL therapy has changed in the last decades with the introduction of antibody-based therapies and novel targeted agents resulting in improved outcomes.

Areas Covered: This article describes the use of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates in the treatment of relapsed and refractory CLL.

BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance.

Introduction: In the last decade, BTK inhibitors and the BCL-2 inhibitor venetoclax have replaced immunochemotherapy in the treatment of CLL.

Areas Covered: This review describes the use of BTK inhibitors and BCL2 inhibitors in the treatment of naive and relapsed or refractory CLL, with particular attention to the mechanisms of resistance. It also addresses the management of double-refractory patients, and the discovery of novel drugs.

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.

The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis with extended follow-up. Overall, 652 patients received zanubrutinib (n = 327) or ibrutinib (n = 325). At an overall median follow-up of 42.

Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.

This multicenter, open-label, phase Ib study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naïve (TN) and relapsed or refractory (R/R) mantle cell lymphoma (MCL). Patients received acalabrutinib from cycle 1 until disease progression or treatment discontinuation, bendamustine on days 1 and 2 of each cycle for up to 6 cycles, and rituximab on day 1 of each cycle for 6 cycles, continuing every other cycle from cycle 8 for 12 additional doses (TN cohort). Eighteen patients enrolled in the TN cohort and 20 in the R/R cohort.

Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a common leukemia characterized by clonal expansion of mature CD5+/CD23 + B cells in the blood, bone marrow (BM) and lymphoid tissues. CLL can undergo extramedullary and extranodal infiltration, with one study noting an incidence of only 0.3 per 100,000 people, and in 17.

Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy.

Objective: To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed by ibrutinib in the second line (1L CT/CIT-2L ibrutinib) after disease progression by emulating a randomized trial comparing both treatment sequences.

Methods: Patient-level data from the RESONATE-2 trial (NCT01722487) and real-world PHEDRA databases were analyzed. Three scenarios were considered using the following data sources: (1) RESONATE-2, (2) combined RESONATE-2/PHEDRA, (3) combined RESONATE-2/PHEDRA for 1L ibrutinib and PHEDRA for 1L CT/CIT-2L ibrutinib.